Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
10.36
+0.19 (1.87%)
At close: Jan 26, 2026, 4:00 PM EST
10.36
0.00 (0.00%)
After-hours: Jan 26, 2026, 4:00 PM EST
Personalis Employees
As of December 31, 2024, Personalis had 229 total employees, including 228 full-time and 1 part-time employees. The number of employees increased by 4 or 1.78% compared to the previous year.
Employees
229
Change (1Y)
4
Growth (1Y)
1.78%
Revenue / Employee
$301,760
Profits / Employee
-$322,633
Market Cap
920.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 229 | 4 | 1.78% | 228 | 1 |
| Dec 31, 2023 | 225 | -174 | -43.61% | 223 | 2 |
| Dec 31, 2022 | 399 | 73 | 22.39% | 395 | 4 |
| Dec 31, 2021 | 326 | 91 | 38.72% | 325 | 1 |
| Dec 31, 2020 | 235 | 53 | 29.12% | 234 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 2,997 |
| Neogen | 2,974 |
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,200 |
| Fulgent Genetics | 1,313 |
| GeneDx Holdings | 1,000 |
| Twist Bioscience | 979 |
| Castle Biosciences | 823 |
PSNL News
- 14 days ago - Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - Business Wire
- 18 days ago - Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - Business Wire
- 5 weeks ago - Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
- 6 weeks ago - New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
- 2 months ago - Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 2 months ago - Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer - Business Wire
- 2 months ago - Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Personalis Reports Third Quarter 2025 Financial Results - Business Wire